Roche To Invest USD 50 Billion In U.S. Pharmaceuticals And Diagnostics Over The Next 5 Years

Roche has announced plans to invest $50 billion in the United States over the next five years. This significant investment aims to further expand Roche’s presence in the country, where it already maintains a substantial footprint with 13 manufacturing sites and 15 research and development (R&D) centers across its Pharmaceuticals and Diagnostics divisions. The investment is expected to generate more than 12,000 new jobs, including approximately 6,500 construction roles and 1,000 positions at newly established or expanded facilities. In addition, it will support the growth of Roche’s current workforce of over 25,000 employees, spread across 24 locations in eight U.S. states.

As part of this initiative, Roche will enhance its manufacturing and distribution capabilities for innovative medicines and diagnostic products in several states, including Kentucky, Indiana, New Jersey, Oregon, and California. The company also plans to establish a state-of-the-art gene therapy manufacturing facility in Pennsylvania, supporting its advancement in next-generation treatments. A new 900,000 square foot manufacturing center will be constructed to accommodate Roche’s growing portfolio of weight loss medications, though the specific location has not yet been disclosed. In Indiana, Roche will develop a new facility dedicated to continuous glucose monitoring, contributing to its efforts in diabetes care.

Thomas Schinecker, Roche Group CEO, said in a statement, “Roche is a Swiss company with a strong heritage in more than 130 countries globally. Today’s announced investments underscore our long-standing commitment to research, development and manufacturing in the US. We are proud of our 110 year legacy in the United States which has been a key driver for jobs, innovation and the creation of intellectual property in the US, across both our Pharmaceutical and Diagnostics Divisions. Our investments of USD 50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world.”

Roche will also strengthen its R&D capabilities through the establishment of a new center in Massachusetts. This facility will focus on cutting-edge artificial intelligence research and act as a hub for the company’s cardiovascular, renal, and metabolism R&D activities. In addition, existing R&D centers in Arizona, Indiana, and California will undergo significant expansion and upgrades to support ongoing scientific innovation.

Once all new and expanded facilities are operational, Roche anticipates that it will export more medicines from the U.S. than it imports. Currently, the Diagnostics division already maintains a positive trade balance, exporting more products from the U.S. to international markets than it imports. This large-scale investment reflects Roche’s long-term commitment to the U.S. healthcare and innovation ecosystem.